back to US directory
us clinical guidance

Vulvovaginal candidiasis

CDC differentiation of uncomplicated, recurrent, severe and non-albicans vulvovaginal candidiasis with pregnancy and resistance boundaries.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team · Clinical editorial review · reviewed 2026-08-20 · due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Symptomatic adolescents and adults with suspected vulvovaginal candidiasis. This page does not cover invasive candidiasis, chronic vulvar dermatoses or every investigational recurrent-VVC product; asymptomatic Candida detection is not itself an indication for treatment.
sources for this section:CDC VVC 2021

The Bottom Line

  • Pruritus, soreness, external dysuria and discharge are not specific for Candida; use examination and microscopy or culture when the diagnosis is uncertain or disease is complicated.
  • Classify vulvovaginal candidiasis as uncomplicated or complicated from recurrence, severity, organism and host factors because evaluation and treatment duration differ.
  • Use a short-course topical azole or source-supported oral option for uncomplicated disease after pregnancy, interaction and liver-risk review.
  • Obtain culture or other species-level testing for recurrent, severe, non-albicans or treatment-refractory symptoms and consider susceptibility when azole resistance is possible.
  • During pregnancy, CDC recommends only topical azoles used for seven days; avoid routine oral fluconazole treatment in pregnancy.
sources for this section:CDC VVC 2021

Practical clinical workflow

1
Ask about itching, pain, discharge, odor, dysuria, pregnancy, diabetes, immunosuppression, antibiotics, recurrence timing, over-the-counter products and prior laboratory confirmation.
2
Inspect vulva and vagina and perform pH and wet preparation with potassium hydroxide; send culture when microscopy is negative despite persistent compatible symptoms.
3
Choose an uncomplicated or complicated regimen and explain that oil-based intravaginal preparations can impair latex barrier protection.
4
For recurrent disease, document the number of proven episodes, induce mycologic remission, then use the CDC maintenance strategy with specialist input for resistance or non-albicans species.
5
Reassess persistent symptoms for BV, trichomoniasis, cervicitis, dermatitis, lichen sclerosus, vulvodynia or another cause instead of escalating antifungals indefinitely.
sources for this section:CDC VVC 2021

Safety boundaries and escalation

  • Pelvic pain, fever, ulcers, pregnancy bleeding, a vulvar mass or systemic illness is not routine candidiasis and requires a broader or urgent assessment.
  • Boric acid is toxic if swallowed and must never be used orally; pregnancy safety and household storage require explicit review before any compounded vaginal use.
  • Oral azoles have hepatic, QT and drug-interaction risks; check current FDA labeling and medication history, especially for repeated or suppressive use.
  • Routine treatment of an asymptomatic partner is unsupported; evaluate a symptomatic partner rather than prescribing automatically.
sources for this section:CDC VVC 2021

Localization

This is a CDC STI-guideline summary using US products and terminology.
sources for this section:CDC VVC 2021

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Centers for Disease Control and PreventionSexually Transmitted Infections Treatment Guidelines, 2021 — Vulvovaginal CandidiasisMMWR 2021;70(No. RR-4) · published 2021-07-23 · accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page’s provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what—if anything—you may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.